Otsaw Launches World’s First UV-C LED Disinfection Autonomous Robot

First Deployment at Wisma Atria, Singapore Starting from 15 July 2020

June 16, 2020

Otsaw Digital Pte. Ltd. (“Otsaw“) announced that it has launched the world’s first UV-C LED Disinfection Autonomous Robot, named “O-RX”. Underscoring Otsaw’s strengths in the design and development of autonomous robotics and the integration of innovative UV-C LED technology, Otsaw has filed the relevant patents for this new innovation.

Otsaw notes from conceptualization, design, materials procurement, prototype testing to certification, the development of the O-RX was successfully completed in a short 8 weeks.

As a testament to its high safety standards and product quality, the O-RX has undergone the relevant safety and testing under various conditions and it has been certified by internationally-accredited TUV SUD.

Eliminating the use of mercury lamps that emits harmful UV-A and UV-B radiations, the O-RX utilises the UV-C LED technology that emits only UV-C light, which is extremely effective when it comes to killing microbes, including harmful bacteria and coronaviruses such as COVID-19. Hence, the UV-C LED technology is much safer and non-cancerous to human skin.

Integrated with the innovative UV-C LED technology, the O-RX has a disinfection rate of more than 99.999% with a range of 2.5 meters and the UV-C LED technology is also more energy-efficient than conventional mercury lamps by 70%.

Capable to be deployed for 5 hours on one full charge, the O-RX is also equipped with a 360-degree camera and lidar sensors with self-driving, collision avoidance and artificial intelligence technologies. The O-RX can be controlled and managed remotely via a fleet management control platform that is developed by Otsaw.

To help remove heat generated by the LED, the robot uses a thermal management solution developed by researchers at the Agency for Science, Technology and Research’s (A*STAR) Singapore Institute of Manufacturing Technology (SIMTech).

Otsaw will be collaborating with YTL Starhill Global REIT Management Limited, the manager of Starhill Global REIT, and will be running a trial of the O-RX at Wisma Atria commencing from 15 July 2020.

Otsaw’s founder and CEO, Mr Ling Ting Ming, commented, “Disinfection is a key part of protecting the health and safety of communities and more than ever, we need to accelerate the rate of automating disinfection as COVID-19 outbreak increased the demand and frequencies of disinfection but at the same time, manpower resources have been curtailed.

“O-RX combines innovative LED technology and robotics to allow the disinfecting process to be fully autonomous, mobile and much safer, thereby achieving a higher disinfection efficiency as compared to conventional methods and reduce the dependence of human resources.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version